OMB Weighs Whether CMS AOM Coverage Rule Could Spur Shortages

The Trump administration appears to be concerned with the possibility of GLP-1 drug shortages if CMS moves forward with expanding coverage for those with obesity, according to a source familiar with recent conversations between the White House budget office and stakeholders. The source told Inside Health Policy that one of the government officials asked whether there was any concern about shortages of anti-obesity medications (AOMs) that would impact the diabetes community if the drugs were covered for a broader...